Adams, Christopher P., and Van V. Brantner. 2006. Estimating the Cost of New Drug Development: Is It Really $802 Million? Health Affairs 25(2): 420–8.
Alston, Richard M., J. R. Kearl, and Michael V. Vaughan. 1992. Is There a Consensus Among Economists in the 1990’s? American Economic Review 82(2) May: 203–9.
American Medical Association (AMA). 1995. Drug Evaluations Annual, 1995. Chicago, Ill.: American Medical Association.
Angell, Marcia. (1997). Science on Trial: The Clash of Medical Evidence and the Law in the Breast Implant Case. New York: W. W. Norton.
Anonymous JEL referee. 2002. Mailed to Daniel Klein by John McMillian, May, 2002.
Arno, P. S., K. Bonuck, and M. Davis. 1995. Rare Diseases, Drug Development, and AIDS: The Impact of the Orphan Drug Act. Milbank Quarterly 73, no. 2: 231–52.
Bakke, O. M., M. Manocchia, de F. Abajom, K. Kaitin, and L. Lasagna. 1995. Drug Safety Discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: A Regulatory Perspective. Clinical Pharmacology and Therapeutics 58, no. 1: 108–17.
Beales, J. Howard, III. 1996. New Uses for Old Drugs. In Competitive Strategies in the Pharmaceutical Industry, edited by R. B. Helms, 281–305. Washington, D.C.: American Enterprise Institute for Public Policy Research.
———. 1997. The Health Consequences of Decisions about Drugs. Unpublished manuscript, George Washington University, Department of Strategic Management and Public Policy.
Bean, William B. 1970. Commentary. In Safeguarding the Public: Historical Aspects of Medicinal Drug Control, edited by J. B. Blake, 132–4. Baltimore: Johns Hopkins University Press.
Becker, Gary. 2002. Get the FDA out of the Way, and Drug Prices will Drop. Business Week (Sept. 16, 2002).
———. 2004. Big Ideas: Patients’ Rights. The Milken Institute Review. Second Quarter, p. 93–4.
Beisler, Joshua H. 2000. Dietary Supplements and Their Discontents: FDA Regulation and the Dietary Supplement Health and Education Act of 1994. Rutgers Law Journal 31: 511–51.
Benham, Lee, and Alexandra Benham. 1975. Regulating through the Professions: A Perspective on Information Control. Journal of Law and Economics 18, no. 2: 421–48.
Berndt, Ernst R. 2005. The United States’ Experience with Direct-to-Consumer Advertising of Prescription Drugs: What Have We Learned? Paper presented at the International Conference on Pharmaceutical Innovation, Taipei, Taiwan. In Frank A. Sloan and Chee-Ruey Hsieh, eds., Promoting and Coping with Pharmaceutical Innovation: An International Perspective. Cambridge University Press, late 2006.
Berndt, Ernst R., Adrian H. B. Gottschalk, Tomas Philipson and Matthew W. Strobeck. 2005a. Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process. Forum for Health Economics & Policy, article 2.
———. 2005b. Industry Funding of the FDA: Effects of PDUFA on Approval Times and Withdrawal Rates, Nature Reviews: Drug Discovery, 4(7), July 2005: 545–54.
Berndt, E.R., R. S. Pindyck, and P. Azoulay. 2000. Consumption Externalities and Diffusion in Pharmaceutical Markets: Anti-Ulcer Drugs. NBER Working Paper #7772.
Berndt, E.R. et al. 1997. The Roles of Marketing, Product Quality, and Price Competition in the Growth and Composition of the US Antiulcer Drug Industry. In T.F Bresnahan and R.J. Gordon, eds., The Economics of New Goods, 58, NBER Studies in Income and Wealth. Chicago: University of Chicago Press: 277–322.
Brown, Walter A. and B. Severs. 1999. Placebos: Fooling the Body to Heal Itself. USA Today (July): 32–33.
Buchanan, James M. 2005. Afraid to Be Free: Dependency as Desideratum. Public Choice 34: 19–31.
Burrow, James G. 1970. The Prescription-Drug Policies of the American Medical Association in the Progressive Era. In Safeguarding the Public: Historical Aspects of Medicinal Drug Control, edited by J. B. Blake, 112–22. Baltimore: Johns Hopkins University Press.
Calfee, John E. 1996. The Leverage Principle in the FDA’s Regulation of Information. In Competitive Strategies in the Pharmaceutical Industry, edited by R. B. Helms, 306–21. Washington, D.C.: American Enterprise Institute for Public Policy Research.
———. 1997. Fear of Persuasion: A New Perspective on Advertising and Regulation. Monnaz, Switzerland: Agora Association with American Enterprise Institute for Public Policy Research.
———. 2000. Prices, Markets, and the Pharmaceutical Revolution. Washington: American Enterprise Institute for Public Policy Research.
———. 2006. Playing Catch-up: The FDA, Science, and Drug Regulation. Health Policy Outlook (5). Washington: American Enterprise Institute for Public Policy Research.
Campbell, N. 2000. Exploring Free Market Certification of Medical Devices. In American Health Care: Government, Market Processes and the Public Interest, edited by R. D. Feldman, 313–44. New Brunswick, N.J.: Transaction Publishers and The Independent Institute.
Cannon, Michael F. 1996. Aspirin Fights Heart Attacks, and the FDA Fights to Hide that Information from Your Doctor. Capitol Comment (149). Citizens for a Sound Economy Foundation.
Carpenter, Daniel P. 2002. Groups, the Media, Agency Waiting Costs, and FDA Drug Approval. American Journal of Political Science 46(3): 490–505.
CDC. 1999. Infant Metabolic Alkalosis and Soy-Based Formula — United States. MMWR Supplements March 3 1999 / 48(LMRK);: 121–3.
Coase, Ronald H. 1982. How Should Economists Choose? Reprinted in Coase’s Essays on Economics and Economists. Chicago: University of Chicago Press, 1994: 15–33.
Comanor, William S. 1986. The Political Economy of the Pharmaceutical Industry. Journal of Economic Literature 24(3): 1178–217.
Conko, G. 1998. A National Survey of Neurologists and Neurosurgeons regarding the Food and Drug Administration. Washington, D.C. Competitive Enterprise Institute, October 5.
Coscelli, Andrea. 2000. The Importance of Doctors’ and Patients’ Preferences in the Prescription Decision. Journal of Industrial Economics 48(3): 349–69.
Danzon, Patricia M., and Eric L. Keuffel. 2007. Regulation of the Pharmaceutical Industry. Paper prepared for the NBER Conference on Regulation, September 2005; paper revised September 12, 2007.
Demsetz, Harold. 1969. Information and Efficiency: Another Viewpoint. Journal of Law and Economics 12(1): 1–22.
DiMasi, Joseph A. 2000. New Drug Innovation and Pharmaceutical Industry Structure: Trends in the Output of Pharmaceutical Firms. Drug Information Journal 34: 1169–94.
———. 2001. New Drug Development in the United States from 1963 to 1999. Clinical Pharmacology and Therapeutics 69(5): 286–96.
DiMasi, Joseph A., and Cherie Paquette. 2004. The Economics of Follow-on Drug Research and Development. Pharmacoeconomics 22(Suppl. 2): 1–14.
DiMasi, Joseph A., Jeffrey S. Brown, and Louis Lasagna. 1996. An Analysis of Regulatory Review Times of Supplemental Indications for Already-Approved Drugs: 1989–1994. Drug Information Journal 30: 315–337.
DiMasi, Joseph A., Ronald W. Hansen, and Henry G. Grabowski. 2003. The Price of Innovation: New Estimates of Drug Development Costs. Journal of Health Economics 22: 151–85.
———. 2005a. Extraordinary Claims Require Extraordinary Evidence. Journal of Health Economics 24(5): 1034–44.
———. 2005b. Setting the Record Straight on Setting the Record Straight: Response to the Light and Warburton Rejoinder. Journal of Health Economics 24(5): 1049–53.
Dowling, Harry F. 1970. The American Medical Association’s Policy on Drugs in Recent Decades. In Safeguarding the Public: Historical Aspects of Medicinal Drug Control, edited by J. B. Blake, 123–31. Baltimore: Johns Hopkins University Press.
Dranove, David, and David Meltzer. 1994. Do Important Drugs Reach the Market Sooner? RAND Journal of Economics 25(3): 402–23.
Dranove, David, and Chris Olsen. 1994. The Economic Side Effects of Dangerous Drug Announcements. Journal of Law and Economics 37(2): 323–48
Ellison, S.F., I. Cockburn, Z Griliches, and J. Hausman. 1997. Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins. RAND Journal of Economics 28(3): 426–46.
Feldman, Roger D. 2000. American Health Care: Government, Market Processes and the Public Interest. New Brunswick, N.J.: Transaction Publishers and The Independent Institute.
Folland, Sherman, Allen C. Goodman, and Miron Stano. 2007. The Economics of Health and Health Care. Pearson Prentice Hall: Upper Saddle River, New Jersey, pp. 362.
Frech, H.E., III, and Richard D. Miller, Jr. 1999. The Productivity of Health Care and Pharmaceuticals: An International Comparison. Washington: The AEI Press.
Friedman, Milton and Rose Friedman. 1990. Free to Choose: A Personal Statement. San Diego: Harcourt Brace Jovanovich.
Gieringer, D. H. 1984. Consumer Choice and FDA Drug Regulation. Ph.D. diss., Department of Engineering-Economic Systems, Stanford University.
———. 1985. The Safety and Efficacy of New Drug Approval. Cato Journal 5, no. 1: 177–201.
Grabowski, H. G. 1980. Regulation and the International Diffusion of Pharmaceuticals. In The International Supply of Medicines, edited by R. B. Helms, 5–36. Washington, D.C.: American Enterprise Institute for Public Policy Research.
Grabowski, Henry G., and John M. Vernon. 1977. Consumer Protection Regulation in Ethical Drugs. American Economic Review 67(1): 359–64.
———. 1983. The Regulation of Pharmaceuticals: Balancing the Benefits and Risks. Washington D.C.: American Enterprise Institute for Public Policy Research.
———. 1996. Longer Patents for Increased Generic Competition in the U.S.: The Waxman-Hatch Act after One Decade. PhamacoEconomics 10, no. 2: 110–23.
Grabowski, Henry G., John M. Vernon, and Lacy Glenn Thomas. 1978. Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry. Journal of Law and Economics 21(1): 133–63.
Grady, Denise. 2001. FDA Pulls a Drug, and Patients Despair. New York Times, 30 January.
Grinspoon, L. 1997. Marihuana, the Forbidden Medicine. 2d ed. New Haven, Conn.: Yale University Press.
Hahn, Robert W. and Paul C. Tetlock. 2008. Has Economic Analysis Improved Regulatory Decisions? Journal of Economic Perspectives 22(1): 67–84.
Hansen, R. W. 2000. Regulation of the Pharmaceutical Industry. In American Health Care: Government, Market Processes and the Public Interest, edited by R. D. Feldman, 269–84. New Brunswick, N.J.: Transaction Publishers and The Independent Institute.
Harris, Steven B. 1992. The Right Lesson to Learn from Thalidomide.
Healy, Elaine, and Kenneth Kaitin. 1999. The European Agency for the Evaluation of Medicinal Product’s Centralized Procedure for Product Approval: Current Status. Drug Information Journal 33: 969–78.
Henderson, David R. 2002. The Joy of Freedom: An Economist’s Odyssey. New York: Prentice Hall.
Higgs, Robert. 1994. Banning a Risky Product Cannot Improve Any Consumer’s Welfare (Properly Understood), with Applications to FDA Testing Requirements. Review of Austrian Economics 7, no. 2: 3–20.
———, ed. 1995a. Hazardous to Our Health? FDA Regulation of Health Care Products. Oakland, Calif.: The Independent Institute.
———. 1995b. How FDA Is Causing a Technological Exodus: A Comparative Analysis of Medical Device Regulation—United States, Europe, Canada, and Japan. Washington, D.C.: Competitive Enterprise Institute, March.
———. 1995c. FDA Regulation of Medical Devices. In Hazardous to Our Health? FDA Regulation of Health Care Products, edited by Robert Higgs, 55–95. Oakland, Calif.: The Independent Institute.
———. 1995d. Diminishing the Harm. In Hazardous to Our Health?: FDA Regulation of Health Care Products, ed. R. Higgs, 97–101. Oakland, CA: Independent Institute.
Holcombe, Randall. 1995. Public Policy and the Quality of Life: Market Incentives versus Government Planning. Westport, CT: Greenwood Press.
Hooper, Charles L. 2008. Pharmaceuticals: Economics and Regulation. In The Concise Encyclopedia of Economics, ed. D.R. Henderson. Indianapolis: Liberty Fund: 388–92.
Hróbjartsson A. and P. C. Gotzsche. 2001. Is the Placebo Powerless? An Analysis of Clinical Trials Comparing Placebo with No Treatment. New England Journal of Medicine 344: 1595-602.
Hurwitz, Mark A. and Richard E. Caves. 1988. Persuasion or Information? Promotion and the Shares of Brand Names and Generic Pharmaceuticals. Journal of Law and Economics 31(2): 299–320.
Ippolito, P.M. 1986. Consumer Protection Economics: A Selected Survey. In Empirical Approaches to Consumer Protection Economics, P.M. Ippolito and D.T. Scheffman, eds.: 1–33. Washington, DC: Federal Trade Commission.
Ippolito, P. M., and A. D. Mathios. 1990. Information, Advertising and Health Choices: A Study of the Cereal Market. Rand Journal of Economics 21 (3): 459–80.
———. 1991. Health Claims in Food Marketing: Evidence On Knowledge and Behavior in the Cereal Market. Journal of Public Policy and Marketing 10 (1): 15–32.
———. 1993. New Food Labeling Regulations and the Flow of Nutrition Information to Consumers. Journal of Public Policy and Marketing 12 (2): 188–205.
———. 1995a. Information and advertising policy: A study of fat and cholesterol consumption in the United States, 1977–1990. Bureau of Economics Staff Report, Federal Trade Commission, Washington, D.C.
———. 1995b. Information and Advertising: The Case of Fat Consumption in the United States. American Economic Review 85 (2): 91–5.
Jarrell, Gregg and Sam Peltzman, 1985. The Impact of Product Recalls on the Wealth of Sellers Journal of Political Economy, University of Chicago Press, vol. 93(3), pages 512–36, June.
Johnson, Kathleen and Shirley Svorny. 2007. Why Shouldn’t Pharmacists Be Prescribers? Los Angeles Times, Oct. 22. Link
Kaitin, Kenneth I., ed. 1999. Clinical Development Times for New Drugs Drop 18%, Reversing 12-Yr Trend. Impact Report 1, July. Boston: Tufts Center for the Study of Drug Development.
———. 2004. Incremental R&D Creates Safer, More Effective Drugs & Fosters Competition. Impact Report 6(6). Boston: Tufts Center for the Study of Drug Development.
———. 2005. Longer Clinical Times Are Extending Time to Market for New Drugs in U.S. Impact Report 7(6). Boston: Tufts Center for the Study of Drug Development.
Kaitin, K. I., and J. A. DiMasi. 2000. Measuring the Pace of New Drug Development in the User Fee Era. Drug Information Journal 34: 673–80.
Kaitin, K. I., and Jeffrey Brown. 1995. A Drug Lag Update. Drug Information Journal 29: 361–73.
Kaitin, K. I., and E. M. Healy. 2000. The New Drug Approvals of 1996, 1997, 1998: Drug Development Trends in the User Fee Era. Drug Information Journal 34: 1–14.
Kaitin, K. I., N. Mattison, F. K. Northington, et al. 1989. The Drug Lag: An Update of New Drug Introductions in the US and UK., 1977 Through 1987. Clinical pharmacology and therapeutics (4): 121–38.
Kaplan, Alan H. 1995. Fifty Years of Drug Amendments Revisited: In Easy to Swallow Capsule Form. Food and Drug Law Journal 50 (special issue): 179–96.
Kaplar, Richard T., ed. 1993. Bad Prescription for the First Amendment: FDA Censorship of Drug Advertising and Promotion. Washington, D.C.: Media Institute.
Kazman, S. 1990. Deadly Overcaution. Journal of Regulation and Social Costs 1, no. 1: 35–54.
Keith, Alison. 1995. Regulating Information about Aspirin and the Prevention of Heart Attack. American Economic Review 85 (May): 96–9.
Klein, Daniel B., ed. 1997. Reputation: Studies in the Voluntary Elicitation of Good Conduct. Ann Arbor: University of Michigan Press.
———. 1998. If Government Is So Villainous, How Come Government Officials Don’t Seem Like Villains?, revised version printed in 3 Libertarian Essays (Irvington, NY: Foundation for Economic Education).
———. 2000a. Assurance and Trust in a Great Society. FEE Occasional Paper No. 2. Irvington, N.Y.: Foundation for Economic Education.
———. 2000b. Policy Medicine Versus Policy Quackery: Economists against the FDA. Knowledge, Technology, and Policy 13 (spring): 92–101.
———. 2002. The Demand for and Supply of Assurance. Chap. 9 in Market Failure or Success: The New Debate, pp. 172–92, edited by Tyler Cowen and Eric Crampton. Cheltenham, UK: Edward Elgar.
Klein, Daniel B. and Charlotta Stern. 2006. Economists’ Policy Views and Voting. Public Choice 126: 331–42.
Klein, D.B. and A. Tabarrok. 2002. Is the FDA Safe and Effective? [a sophisticated Web site of 35,000 words reviewing economic analysis of the FDA] Online at www.FDAReview.org. A project of the Independent Institute.
———. 2004. Who Certifies Off-Label? Regulation, Summer 2004: 60–3. Link
———. 2008. Do Off-Label Drug Practices Argue against FDA Efficacy Requirements? A Critical Analysis of Physicians’ Argumentation for Initial Efficacy Requirements. American Journal of Economics and Sociology.
Kleinfeld, Vincent A. 1970. Commentary and participation in Discussion. In Safeguarding the Public: Historical Aspects of Medicinal Drug Control, edited by J. B. Blake, 180–5 and 189–95. Baltimore: Johns Hopkins University Press.
Kohn, Linda T., Janet M. Corrigan, and Molla S. Donaldson, eds. 1999. To Err Is Human: Building a Safer Health System. Washington, D.C.: National Academy Press.
Krauss, Michael I. 1996. Loosening the FDA’s Drug Certification Monopoly: Implications for Tort Law and Consumer Welfare. George Mason Law Review 4 (spring): 457–83.
Krugman, Paul. 2000. Natural Born Killers. New York Times, March 22: A27.
———. 2007. Fear of Eating. New York Times, May 21: A19.
Kuran, Timur. 1995. Private Truths, Public Lies: The Social Consequences of Preference Falsification. Cambridge: Harvard University Press.
Lazarou, Jason, et al. 1998. Incidence of Adverse Drug Reactions in Hospitalized Patients. Journal of the American Medical Association 279, no. 15: 1200–05.
LeBlanc, Stephen, and Rob Sabados. 1996. Oxandrolone Background. Bay Area Reporter, July 11.
Leffler, Keith B. 1981. Persuasion or Information? The Economics of Prescription Drug Advertising. Journal of Law and Economics 24, 1: 45–74.
Lewin, Peter. 2007. Facts, Values, and the Burden of Proof. The Independent Review 11(4): 503–17.
Libecap, Gary D. 1992. The Rise of the Chicago Packers, and the Origins of Meat Inspection and Antitrust. NBER Historical Working Paper No. 29. Economic Inquiry (April 1992): 242–62.
Lichtenberg, F. R. 1996. Do (More and Better) Drugs Keep People Out of Hospitals? American Economic Review 86 (2): 384–88.
———. 2001a. The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey. NBER Working Paper Series 8147.
———. 2001b. The Effect of New Drugs On Mortality from Rare Diseases and HIV. NBER Working Paper Series 8677.
Light, Donald W., and Rebecca N. Warburton. 2005a. Extraordinary Claims Require Extraordinary Evidence. Journal of Health Economics 24(5): 1030–3.
———. 2005b. Setting the Record Straight in the Reply by DiMasi, Hansen and Grabowski. Journal of Health Economics 24(5): 1045–8.
Ling, Davina C., Ernst R. Berndt, and Margaret K. Kyle. 2002. Deregulating Direct-to-Consumer Marketing of Prescription Drugs: Effects on Prescription and Over-the-Counter Product Sales. Journal of Law and Economics 45, Oct: 691–721.
Masson, Alison, and Paul H. Rubin. 1985. Matching Prescription Drugs and Consumers. New England Journal of Medicine 313 (August 22): 513–5.
———. 1986. Plugs for Drugs. Regulation (Sept./Oct.): 37–44.
McCloskey, Deirdre N., and Stephen T. Ziliak, 1996. The Standard Error of Regressions. Journal of Economic Literature 34: 97–114.
McMillan, John. 2002. Correspondence to Daniel Klein, May 21.
Meyers, A. S. 1991. The U.S. Orphan Drug Act: Should the Law Cover Highly Profitable Drugs? World Pharmaceutical Standards Review 1: 24–5.
Miller, Henry I. 1998. Failed FDA Reform. Regulation 21, no. 3: 24–30.
———. 2000. To America’s Health: A Proposal to Reform the Food and Drug Administration. Stanford, Calif.: Hoover Institution Press.
Moore, Thomas J. 1995. Deadly Medicine. New York: Simon and Schuster.
Munsey, Rodney R. 1995. Medical Device Regulation. Food and Drug Law Journal 50 (special issue): 163–77.
Niskanen, William. 1971. Bureaucracy and Representative Government. Chicago: Aldine.
Olson, Mary K. 1995. Regulatory Agency Discretion Among Competing Industries: Inside the FDA. Journal of Law, Economics, and Organization 11 (2): 379–405.
———. 1997. Firm Characteristics and the Speed of FDA Approval. Journal of Economics and Management Strategy 6 (2): 377–401.
———. 1999. Agency Rulemaking, Political Influences, Regulation, and Industry Compliance. Journal of Law, Economics, and Organization 15 (3): 573–601.
———. 2004. Are novel drugs more risky for patients than less novel drugs? Journal of Health Economics 23, 1135–58.
Parkinson, Thomas L. 1975. The Role of Seals and Certifications of Approval in Consumer Decision-Making. Journal of Consumer Affairs 9 (summer): 1–14.
Pasour, E. C., Jr. 1998. We Can Do Better Than Government Inspection of Meat. The Freeman (May 1998).
Pearson, Durk, and Sandy Shaw. 1993. Freedom of Informed Choice: FDA Versus Nutrient Supplements. Neptune, N.J.: Common Sense.
———. 1999. FDA TKO. Liberty (April): 27–9.
Peltzman, S. 1973. An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments. Journal of Political Economy 81, no. 5: 1049–91. Reprinted in Chicago Studies in Political Economy, edited by George J. Stigler, 303–48. Chicago, University of Chicago Press, 1988.
———. 1974. Regulation of Pharmaceutical Innovation: The 1962 Amendments. Washington, D.C.: American Enterprise Institute for Public Policy Research.
———. 1987a. Regulation and Health: The Case of Mandatory Prescriptions and an Extension. Managerial and Decision Economics 8(1): 41–6.
———. 1987b. The Health Effects of Mandatory Prescriptions. Journal of Law and Economics 30(2): 207–38.
———. 2005. Regulation and the Natural Progress of Opulence. Washington: AEI-Brookings Joint Center on Regulatory Studies, pp. 15–6.
Phelps, Charles. 2003. Health Economics, 3rd Ed. Boston: Addison-Wesley, p. 543.
Philipson, Tomas J., Ernst R. Berndt, Adrian H. B. Gottschalk, and Matthew W. Strobeck. 2006a. How Safe Is Too Safe? Innovation at the FDA. Milken Institute Review (Second Quarter): 545–54.
———. 2006b. Assessing the Safety and Efficacy of the FDA: the Case of the Prescription Drug User Fee Acts, NBER Working Paper 11724, October. Available at www.nber.org/papers/w11724.
Philipson, Tomas and Eric Sun. 2008a. Regulating the Safety and Efficacy of Prescription Drugs. Vox, 3 January.
———. 2008b. Is the Food and Drug Administration Safe and Effective? Journal of Economic Perspectives 22(1): 85–102.
Pinco, R. G., and P. D. Rubin. 1996. Ambiguities of the Dietary Supplement Health and Education Act of 1994. Food and Drug Law Journal 51: 383–405.
Rawlins, Michael D. 2004. Cutting the Cost of Drug Development? Nature Reviews 3: 360–4.
Ross, M.F. 1996. FDA Proposes Labelling Aspirin for Use at Onset of Heart Attack. University of Florida, News and Public Affairs Press Release (June 14).
Rothenberg, Jerome. 1993. Social Strategy and the Tactics in the Search for Safety. Critical Review 7: 159–80.
Rubin, Paul H. 1991a. Economics of Prescription Drug Advertising. Journal of Research in Pharmaceutical Economics 3: 29–41.
———. 1991b. The Economics of Regulating Deception. Cato Journal 10: 667–90.
———. 1994. Are Pharmaceutical Ads Deceptive? Food and Drug Law Journal 49: 7–19.
———. 1995. FDA Advertising Restrictions: Ignorance Is Death. In Hazardous to Our Health? FDA Regulation of Health Care Products, edited by Robert Higgs, 29–53. Oakland, Calif.: The Independent Institute.
———. Ignorance Is Death: The FDA’s Advertising Restrictions. In American Health Care: Government, Market Processes, and the Public Interest, ed. Roger D. Feldman: 285–311. New Brunswick, NJ: Transaction Publishers.
———. 2004. An Opportunity Or a Threat: How to Have Safer, Less Expensive Drugs. The Independent Institute, December 7, 2004.
———. 2005. An Uncertain Diagnosis. Regulation 28(2): 34–9.
Scherer, F.M. 2000. The Pharmaceutical Industry. In Handbook of Health Economics, ed. Anthony J. Cuyler and Joseph P. Newhouse, Amsterdam: Elsevier, 1301.
Schwartzman, David. 1975. The Expected Return from Pharmaceutical Research: Sources of New Drugs and the Profitability of R&D Investment. Washington, D.C.: American Enterprise Institute.
Smith, Adam. 1790. The Theory of Moral Sentiments. Indianapolis: University of Glasgow/Oxford University Press edition reprinted by Liberty Fund, 1982.
Sobel, Russell S. 2002 Public Health and the Placebo: The Legacy of the 1906 Pure Food and Drug Act. Cato Journal 21 (3), Winter: 463–79.
Sonnedecker, Glenn. 1970. Contribution of the Pharmaceutical Profession toward Controlling the Quality of Drugs in the Nineteenth Century. In Safeguarding the Public: Historical Aspects of Medicinal Drug Control, edited by J. B. Blake, 97–111. Baltimore: Johns Hopkins University Press.
Starr, Paul. 1982. The Social Transformation of American Medicine. New York: Basic.
Statman, Meir. 1983. Competition in the Pharmaceutical Industry: The Declining Profitability of Drug Innovation. Washington, D.C.: American Enterprise Institute for Public Policy Research.
Stigler, George J. 1961. “The Economics of Information.” Journal of Political Economy 69, June: 213–25.
Tabarrok, Alexander. 2000. Assessing the FDA via the Anomaly of Off-Label Drug Prescribing. The Independent Review 5, no. 1: 25–53.
———. 2002. The Blessed Monopolies. Regulation, Winter.
Temin, Peter. 1979. The Origin of Compulsory Drug Prescriptions. Journal of Law and Economics 22(1): 91–105.
———. 1980. Taking Your Medicine: Drug Regulation in the United States. Cambridge, Mass.: Harvard University Press.
———. 1992. Realized Benefits from Switching Drugs. Journal of Law and Economics 35: 351–69.
Thomas, L. G. 1990. Regulation and Firm Size: FDA Impacts on Innovation. Rand Journal of Economics 21, no. 4: 497–517.
———. 1996. Industrial Policy and International Competitiveness in the Pharmaceutical Industry. In Competitive Strategies in the Pharmaceutical Industry, ed. Robert B. Helms. Washington: American Enterprise Institute for Public Policy Research 107–29.
Tollison, Robert. 1996. Institutional Alternatives for the Regulation of Drugs and Medical Devices. In Advancing Medical Innovation: Health, Safety, and the Role of Government in the 21st Century, edited by Ralph Epstein, 17–40. Washington, D.C.: Progress and Freedom Foundation.
U.S. Food and Drug Administration. 2004. Brief Summary: Disclosing Risk Information in Consumer-Directed Print Advertisements (Draft Guidance for Industry).
Viscusi, W. Kip. 1996. “Regulatory Reform and Liability for Pharmaceuticals and Medical Devices,” Advancing Medical Innovation: Health, Safety and the Role of Government in the 21st Century. The Progress and Freedom Foundation, February 7, 1996: 79–102.
Viscusi, W. Kip, Joseph E. Harrington, Jr., and John M. Vernon. 2005. Economics of Regulation and Antitrust 4th edition. Cambridge: MIT Press.
Volokh, Alexander. 1995. Clinical Trials: Beating the FDA in Court. Reason (May).
———. 1997. Software Pirates. Reason (November).
Ward, Michael R. 2002. Drug Approval Overregulation. Regulation, Fall: 47–53.
Wardell, W. M. 1973. Introduction of New Therapeutic Drugs in the United States and Great Britain: An International Comparison. Clinical Pharmacology and Therapeutics 14, no. 5: 773–90.
———. 1978a. A Close Inspection of the “Calm Look.” Journal of the American Medical Association 239, no. 19: 2004–11.
———. 1978b. The Drug Lag Revisited: Comparisons by Therapeutic Area of Patterns of Drugs Marketed in the U.S. and Great Britain from 1972 through 1976. Clinical Pharmacology and Therapeutics 24: 499–524.
Wardell, W. M., and L. Lasagna. 1975. Regulation and Drug Development. Washington, D.C.: American Enterprise Institute for Public Policy Research.
Weidenbaum, Murray. 1993. Are Drug Prices Too High? The Public Interest (summer): 84–9.
Weimer, David Leo. 1982. Safe—and Available—Drugs. In Instead of Regulation: Alternatives to Federal Regulatory Agencies, edited by R. W. Poole, 239–83. Lexington, Mass.: D. C. Heath.
Wiggins, S. N. 1981. Product Quality Regulation and New Drug Introductions: Some New Evidence from the 1970s. Review of Economics and Statistics 63: 615–9.
Wildavsky, Aaron. 1988. Searching for Safety. New Brunswick, N.J.: Transaction Publishers.
———. 2000. Regulation of Carcinogens: Are Animal Tests a Sound Foundation? In Cutting Green Tape: Toxic Pollutants, Environmental Regulation and the Law, edited by R. L. Stroup and R. E. Meiners, 251–80. New Brunswick, N.J.: Transaction Publishers and The Independent Institute.
Williams, Walter. 1996. The FDA Dawdles While Patients Are Dying. Orange County Register, May 15.
Willman, David. 2000. How a New Policy Led to Seven Deadly Drugs. Los Angeles Times, Dec. 20.
Woelk, H. 2000. Comparison of St. John’s Wort and Imipramine for Treating Depression: Randomised Controlled Trial. British Medical Journal 321: 536–9.
Young, James Harvey. 1970. Drugs and the 1906 Law. In Safeguarding the Public: Historical Aspects of Medicinal Drug Control, edited by J. B. Blake, 147–57. Baltimore: Johns Hopkins University Press.
Additional Health Care References from The Independent Institute.